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T follicular helper (Tfh) cells are a specialized subset of CD4+ T cells that collaborate with
B cells to promote and regulate humoral responses. Unlike other CD4+ effector lineages,
Tfh cells require interactions with both dendritic cells (DCs) and B cells to complete
their differentiation. While numerous studies have assessed the potential of different DC
subsets to support Tfh priming, the conclusions of these studies depend heavily on the
model and method of immunization used. We propose that the location of different DC
subsets within the lymph node (LN) and their access to antigen determine their potency in
Tfh priming. Finally, we provide a three-step model that accounts for the ability of multiple
DC subsets and related lineages to support the Tfh differentiation program.
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Tfh CELLS IN IMMUNITY
It was initially believed that B cell activation and antibody production were regulated by the Th2
CD4+ T cell effector subset. Yet a principal role of effector T cells in the immune response is to
deal with pathogens or tissue damage, most often outside of secondary lymphoid organs (SLOs).
Indeed, upon activation, effector T cells rapidly downregulate homing receptors that keep them
in the lymph node, thereby enabling migration to affected tissues. It was therefore unclear how
CD4+ T cell help for B cells in the follicles could occur until the discovery of T follicular helper
(Tfh) cells. Tfh cells are a subset of CD4+ T cells that function in the lymph node (LN) and spleen
to promote survival, affinity maturation, and class switch recombination of B cells (1, 2). Tfh cells
express high levels of a cell cycle inhibitor called programmed cell death-1 (PD-1), inducible T cell
co-stimulator (ICOS) and the chemokine receptor CXCR5. CXCR5 expression localizes Tfh cells to
B cell-rich areas of SLOs. These markers, in combination with the lineage-defining transcription
factor BCL6, allow identification of the Tfh subset by flow cytometry [for review see (3)]. Discovery
and characterization of the Tfh subset has illuminated the pathology underlying numerous diseases
such as lupus as well as providing a clearer understanding of a primary cellular regulator of effective
vaccine responses (4).
STAGES OF Tfh INDUCTION
How are Tfh cells induced during an immune response? It is clear that dendritic cells (DCs)
and B cells must cooperate to induce and then solidify the Tfh fate (5–9). The DC phase occurs
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over the first couple of days following T cell recognition of
cognate antigen and induces a “pre-Tfh” state. In the absence
of further interactions with an activated B cell, these nascent
Tfh cells dissipate (10, 11). Instead, if the B cell phase ensues,
a “committed” Tfh cell is produced that has the ability to
enter the germinal center (GC) and in turn promote B cell
proliferation, class switching, and affinity maturation. Using
murine immunization models that provide high concentrations
of antigen together with an adjuvant, the first DC phase can be
bypassed by B cells or monocytes and plasmacytoid DCs (pDCs)
(12). However, under most immunization conditions, MHCII-
expressing DCs are both necessary and sufficient to induce pre-
Tfh cells (6). As we will review, recent work has illuminated the
nature of the DC subset capable of this step during particular
types of immunizations. In both mouse and man, Tfh cells can
be divided into additional subsets based on their differential
expression of cytokines and chemokine receptors (13, 14). These
Tfh subsets have been proposed to promote particular antibody
isotypes from B cells. For example, Tfh1 cells express IFNγ, are
produced during a type 1 immune response and can direct IgG2
class switching (13). DCs may also play an important role in
the polarization of particular Tfh subsets. Indeed, Pattarini et al.
recently showed that human Thymic Stromal Lymphopoietin
(TSLP)-activated DCs seem to favor the polarization of naïve T
cells into Tfh2 cells (15). However, how the different Tfh fates are
induced and the particular role of DCs in guiding differentiation
remains to be fully elucidated and is an area of active research.
DENDRITIC CELL SUBSETS
DCs are a heterogeneous population of cells, which can be
classified as conventional DCs (cDCs) and non-conventional
DCs (plasmacytoid DCs, monocyte-derived DCs, and
Langerhans cells) (Figure 1). cDCs are the primary population
responsible for naïve T cell activation and they express the
transcription factor ZBTB46 (16, 17). cDCs can be further
divided into two subsets based on ontogeny: type 1 cDC1s that
develop in a BATF3/IRF8-dependent manner and type 2 cDC2s
that are IRF4-dependent (18). These two cDC populations differ
in cell surface marker expression, cytokine production, antigen
processing and reside in distinct locations at steady state (18).
Tissue cDC1s and cDC2s survey for infection or host damage,
which if detected, induces DC migration to draining LNs. In
contrast, LN-resident cDC1s and cDC2s acquire antigen that
drains via lymphatics into LNs or is carried to LNs by migratory
cells (19). These distinctions make each cDC subset specialized
to drive particular T cell responses (20–22).
Non-conventional DCs are more diverse in their ontogeny
and function. Plasmacytoid DCs (pDCs) are a unique subset that
sense viral and bacterial pathogens and release high levels of
type I interferons (IFN-I), stimulating both innate and adaptive
immune cells. However, in comparison to cDCs, pDCs have a
limited potential for antigen presentation (23). In mice there
are two main monocyte subsets: inflammatory monocytes and
patrolling monocytes (24). Inflammatory monocytes, including
monocyte-derived DCs (moDCs), are recruited to infected tissue
where they produce inflammatory cytokines to drive local
and systemic inflammation. Patrolling monocytes reside in the
vasculature where they regulate homeostasis of the endothelium
and promote the resolution of inflammation in damaged tissues.
Finally, Langerhans cells (LCs), which have little to no expression
of ZBTB46, are considered part of the macrophage lineage
and are self-renewing in the epidermis. In fitting with this
distinction, LCs have important functions within the tissue
where they modulate the properties of other immune cell types
and contribute to tissue homeostasis. However, LCs also share
functional overlap with cDCs, in that they are able to acquire
antigen in peripheral tissues, migrate to the lymph nodes and
activate naïve T cells (25).
WHICH DC SUBSETS CONTROL Tfh
DIFFERENTIATION?
While DCs have been shown to prime the first stage of Tfh
cell differentiation, much debate exists around the exact DC
subset that is primarily responsible for driving this response in
vivo. A likely major reason for this controversy is differences in
the approaches used. These include the site of immunization,
nature of the antigen used, the dose administered, timepoint
of analyses, use of antigen targeting and the kinetics of the
response. Given the right experimental conditions, most DC
subsets can prime Tfh cells; however, the relative contribution
of each subset to the generation of humoral responses under
physiologic conditions remains less clear. Below we review the
current literature describing the evidence for each DC subset in
Tfh priming and provide a discussion of the interpretations and
caveats for each in the context of the experimental systems used.
LYMPH NODE-RESIDENT VS. MIGRATORY
DCs IN Tfh PRIMING
As described previously, DCs are found both in non-lymphoid
tissues like the skin, lung and gut, as well in SLOs. Both
migratory and LN-resident DCs have been implicated in
driving humoral responses. Most studies comparing these
DC subsets were performed using antigens administered in
the skin, either intradermally, or sub-cutaneously (including
footpad immunization). Following immunization, antigen-
bearing migratory DCs arrive in the lymph nodes after 18–
24 h (26). However, injection of antigen into the footpad or ear
pinnae results in an almost instantaneous delivery of antigen
to the draining LN, perhaps due to the pressure induced by
injection into a limited tissue space (26–31), bypassing the need
for antigen delivery by migratory DCs. It is important to bear
this caveat in mind when interpreting experiments using these
routes of immunization. Nevertheless, this route has been used to
dissect the relative contribution of LN-resident versus migratory
DCs to Tfh priming in a model referred to as the “van Gogh
approach” (29). In this model, antigen is delivered intradermally
in the ear pinnae of mice followed by immediate resection
of the injection site. This effectively eliminates migratory DC-
dependent antigen transport to lymph nodes, limiting humoral
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FIGURE 1 | DC subsets and related lineages. DC subsets and related lineages can be annotated based on ontogeny and function. Monocyte-macrophage DC
progenitors (MDPs) differentiate into monocytes and common dendritic cell progenitors (CDPs). Monocytes further differentiate into patrolling monocytes, inflammatory
monocytes (including moDCs) and Langerhans cells. Langerhans cells also develop from embryonic precursors. CDPs in turn give rise to both pDCs and pre-cDCs,
which are uniquely marked by the transcription factor ZBTB46. Development of cDC2s and cDC1s from the pre-cDC is dependent on IRF4 and BATF3/IRF8,
respectively. Cell surface markers used for identification of each cell type are listed.
responses to those driven by LN-resident DCs. Resecting the
ear actually does not impact the total amount of antigen
reaching the lymph nodes because the majority is delivered
immediately via lymphatics (31). Using this approach, different
studies demonstrated strikingly different results.
Intradermal vaccination in the ear pinnae withUV-inactivated
influenza resulted in similar antibody responses and protection
against a lethal dose of influenza in van Gogh mice as
compared to controls without resection. While Tfh responses
were not evaluated, the study showed that a subset of LN-
resident cDC1s and cDC2s acquire viral antigens within 40min
of immunization, migrate to the inter-follicular regions of
the lymph nodes and engage with antigen-specific T cells
(29). These results were reproduced in a similar study by
Tozuka et al. who demonstrated that intradermally administered
fluorescently-labeled antigen was acquired by a population of
CD11b-expressing DCs (presumably the LN-resident cDC2s)
within 30min of immunization (28). In this study, they also
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showed that ear resection immediately after (<5 s) intradermal
administration of influenza HA vaccine did not impact antibody
responses to the vaccine (28). Gerner et al. used advanced
microscopic techniques as well as the van Gogh approach to
demonstrate that LN-resident cDC2s were important for Tfh
cell priming (27). Although immunization with OVA-coated
beads and CpG did generate significant antibody responses
in van Gogh mice, the levels of the OVA-specific IgG were
significantly higher in control mice, presumably augmented by
the action of migratory DCs (27). Together these studies suggest
that LN-resident cDC2s are sufficient for Tfh priming under
experimental conditions which circumvent the requirement for
antigen delivery through DC migration.
In contrast to these three studies, also using the van Gogh
model, Levin and colleagues showed that migratory DCs are
required to drive Tfh and B cell responses to HIV p24-coated
nano-particles and that LN-resident DCs could not support
either Tfh or GC B cell dependent antibody responses (31). Using
antigen encapsulated in large beads that cannot free drain into
lymph, we recently demonstrated that migratory cDC2s were
sufficient to induce Tfh cell priming and antibody production
(30). In this model, LN-resident DCs could cooperate with
migratory DCs through antigen transfer, but they were not
capable on their own to induce Tfh priming.
So why these discrepancies between the studies? One
explanation could be the nature of the antigen used. The studies
by Woodruff et al. (29) and Tozuka et al. (28) used influenza
as a model system either employing UV-inactivated influenza or
influenza-derived HA protein, respectively. Resident DCs might
have a higher affinity for acquiring influenza antigen and thus use
of these antigens might better target LN-resident DCs. Indeed,
Gonzalez and colleagues demonstrate that a SIGNR1+ DC subset
located in the medullary sinus of the LN preferentially bound
UV-inactivated PR8 strain of influenza and migrated toward
the B cell follicles (32). These DCs are most likely LN resident
cDC2s that are located near the lymphatic sinus (27). However,
it is important to note that blocking PR8 uptake by SIGNR1+
DCs did not significantly impact specific antibody responses to
influenza (32).
It is also possible that not all antibody responses generated
against influenza are Tfh cell-dependent. In line with this, anti-
influenza IgG2b/c but not IgG1 antibodies are generated in Tfh
cell-deficient mice and confer protective immunity to mice upon
lethal influenza challenge (33). This study suggests that while
IgG1 responses require a germinal center phase, Th1 cells are
sufficient to provide B cell help for extrafollicular IgG2 induction
against influenza (33). Indeed, in the study by Woodruff et al.
they do observe a trend for decreased anti-influenza IgG1 but not
IgG2b in van Gogh mice as compared to control mice (29).
These data suggest that resident DCs can drive humoral
responses under certain conditions, such as intradermal
influenza vaccination (28, 29, 32). Under these conditions, a
significant amount of antigen freely drains to the lymph node,
bypassing the need for migratory cDCs. However, under limiting
doses of antigen, LN-resident DCs may not be necessary for
priming Tfh cells. A major hurdle in addressing this possibility
is the lack of tools to selectively deplete LN-resident DC subsets
while keeping migratory DCs intact. Further, distinct routes of
antigen transport ensure that both resident cDCs and migratory
cDCs access antigen and can present antigen to naïve T cells
(Figure 2). This suggests that migratory cDCs and resident cDCs
might regulate distinct steps of Tfh cell differentiation, as will be
discussed later.
CONVENTIONAL DCs
cDCs have been shown to play a dominant role in priming
T effector responses (23). Hence, it is not surprising that they
also are implicated in priming Tfh cells. The recently identified
transcription factor ZBTB46 is specifically expressed by cDCs
and mice encoding a diphtheria toxin receptor under the Zbtb46
promoter (Zbtb46-DTR) can be used to selectively deplete cDCs
in vivo (16, 17). Using these mice, we and others have shown
the loss of T-cell dependent humoral responses in the absence of
cDCs (27, 34, 35). Both cDC1s and cDC2s have been shown to
drive antibody responses (see below). Identification of the most
relevant cDC subset for Tfh priming is complicated by the fact
that there are migratory and LN-resident subsets of cDCs and—
as described above–depending on the route of immunization, the
organ system studied, and type of antigen used, both migratory
and resident cDCs have been implicated in priming Tfh cells.
cDC1s
Like LCs, skin-resident cDC1s, also express Langerin and hence
some of the studies implicating LCs in humoral responses have
also studied the role of cDC1s in mediating these responses.
Using human Langerin-DTA mice (which lack LCs, but not
cDC1s), Yao et al. demonstrated that targeting antigens to
cDC1s (using antibodies against murine Langerin) in the skin is
sufficient to prime Tfh cells. Further, cDC1s promoted humoral
responses, albeit less efficiently than LCs in this model (36).
Antigens can be efficiently targeted to cDC1s in the spleen via
specific receptors such as CLEC9A or DEC-205. In two separate
studies, Caminschi and colleagues demonstrate that targeting
antigen (either OVA or Herpes Simplex Virus glycoprotein 1B)
via CLEC9A, even in the absence of an adjuvant, primed efficient
Tfh and GC B cell responses. Interestingly, they suggest that
increased persistence of anti-CLEC9A mAb (and thus antigen)
in the system drives enhanced CD4+ T cell activation and Tfh
cell priming (37, 38). The authors noted that DEC-205 targeting
is not as efficient in priming humoral responses especially in the
absence of an adjuvant, potentially due to enhanced clearance
of the mAb from circulation (38). These results were also
reproduced in a separate study by Shin and colleagues (39).
In contrast, Levin and colleagues show that while depletion
of LCs does partly abrogate Tfh cell and GC B cell responses to
HIV p24 coated nano-particles, additional depletion of cDC1s
has no further impact on these responses (31). In a similar
approach, Kumamoto et al. using murine Langerin-DTR mice
(to deplete both LCs and cDC1s) also show that cDC1s do not
drive antibody responses to OVA and papain immunization in
the skin (40). Batf3−/− mice, which fail to develop cDC1s also
have no defect in (and in some cases enhanced) Tfh and antibody
responses to inhaled (30) and systemic antigens (34, 35). These
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FIGURE 2 | Modes of antigen access by DCs. (a) Migratory cDCs (and LCs—not depicted) phagocytose antigen in the tissue and then migrate to the LNs. cDC1s
migrate to the T cell zone whereas cDC2s migrate to the T-B border. (b) LN-resident cDC2s lining the lymphatic sinus phagocytose free draining antigen from the
lymphatics. (c) Antigen transported by migratory DCs can be transferred to resident DC subsets in the LNs. LS (lymphatic sinus), SCS (sub-capsular sinus), MS
(Marginal sinus).
results suggest that while targeting antigen to cDC1s could drive
humoral responses, cDC1s are not necessary to prime Tfh and
GC B cell responses to untargeted antigens, as in the case of
vaccination and infection.
cDC2s
It is well documented that irrespective of the organ system,
cDC2s are superior to cDC1s in their ability to prime CD4+ T
cells rather than CD8+ T cells (20, 34, 41, 42). Similarly, several
reports show that cDC2s are the dominant Tfh-priming DC
subset (27, 30, 35, 39), potentially due to their unique localization
(30, 43). Tfh cell priming occurs in the T cell-B cell border (44),
which includes the interfollicular zone (IFZ). We and others have
clearly demonstrated that cDC2s occupy the T-B border regions
in the lymph nodes (30, 43, 45) and the spleen (35, 46–49),
suggesting that this subset of DCs is ideally positioned to prime
Tfh responses.
A number of studies, including ours, have investigated the
role of splenic cDC2s in driving humoral responses to blood-
derived antigens. Using DC-specific IRF4 knockout mice, we
demonstrated that splenic cDC2s, but not cDC1s drive allo-
antibody responses to transfused red blood cells (RBCs) (34).
Similarly, EBI2, a Gαi-coupled receptor, is required by cDC2s to
position themselves in the bridging channels of the spleen, and
Ebi2−/− mice have impaired GC B cell responses to transfused
sheep RBCs (48, 49). In line with this, the same authors in another
report demonstrate that mice deficient in cDC2s (Cd11cCre
Irf4−/−and Cd47−/−), but not cDC1s (Batf3−/−), also have
impaired Tfh responses to sheep RBCs (35). In agreement, but
using an alternative approach, Shin and colleagues showed that
targeting antigens to cDC2s using antibodies against the cDC2-
specific cell surface marker DCIR2 efficiently induced Tfh cell,
GC B cell, and antibody responses to OVA (39, 47).
We recently reported that cDC2s also play a critical role
in driving Tfh-dependent humoral responses (30). We showed
that DC-specific deletion of the guanine nucleotide exchange
factor Dock8 results in impaired migration of cDC2s in the
skin, lungs, and the spleen (30, 46, 50). DOCK8-deficient
mice, but not Batf3−/− (that lack all cDC1s), have defective
Tfh cell responses to antigen administered sub-cutaneously,
intravenously, or intranasally. As discussed previously, antigen
targeting to dermal cDC1s has been shown to efficiently induce
Tfh cell responses (36). However, the skin contains far fewer
cDC1s than cDC2s and hence, antigen administered sub-
cutaneously is not efficiently transported by cDC1s (30). In fact,
most of the antigen administered sub-cutaneously is transported
to the LN by migratory cDC2s. In order to compare migratory
cDC1s to cDC2s, we administered antigen intranasally and found
that both migratory cDC subsets efficiently transported antigens
to the mediastinal LN. However, as in the skin, DC-specific
DOCK8-deficient mice had impaired Tfh cell priming as well as
impaired antigen-specific humoral responses to both OVA and
influenza (as measured by antigen-specific IgG and weight loss in
response to a lethal influenza infection). We noted similar defects
in Cd11cCre Irf4−/− mice which lack cDC2s. In contrast, loss of
cDC1s in BATF3-deficient mice did not impact OVA-specific Tfh
cell differentiation. In a recent study, Kumamoto et al. usedMgl2-
DTR mice to ablate a subset of cDC2s which express CD301b.
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They determined that CD301b+ cDC2s inhibit Tfh cell responses
to antigens administered with Th2-promoting adjuvants such as
papain, but not in response to Th1 adjuvants like CpG (40).
Although the mechanism remains to be determined, this work
highlights that the major DC subsets outlined in Figure 1 are
likely more heterogeneous than currently appreciated.
While these reports suggest that there is some consensus
about the proficiency of cDC2s in Tfh cell priming, discrepancies
do exist, especially regarding the role for migratory versus LN-
resident cDC2s. In an elegant study using an advanced multi-
parameter microscopic technique called histo-cytometry, Gerner
and colleagues showed that migratory cDC2s occupy the IFZ
(part of the T-B border) in inguinal LNs, while resident cDC2s
are found in the lymphatic/medullary sinus regions (27). Based
on this observation, one could hypothesize that migratory cDC2s
are better positioned to drive Tfh responses; however, this study
found that migratory cDC2s were not required for Tfh induction.
Again, this was using methods of immunization that might
bypass normal trafficking routes such as intra-auricular injection
(31). To distinguish the migratory cDC2s from resident cDC2s
(and cDC1s), we used OVA-encapsulated beads that cannot free
drain to the lymph nodes via the lymphatics and hence can only
be transported bymigratory cDCs. Administration of these beads
to DOCK8-deficient mice resulted in impaired Tfh cell responses,
re-emphasizing the inability of cDC1s to drive these responses. In
BATF3-deficient mice, cDC2s are unaffected and administration
of beads to these mice restricts antigen to migratory cDC2s.
Tfh cell frequencies in BATF3-deficient mice were normal as
compared to WT controls, indicating that migratory cDC2s are
sufficient to prime Tfh cell responses (30).
The overall conclusion from these studies is that cDC2s play a
dominant role in priming Tfh cells. However, as will be discussed
next, other non-conventional DCs likely partner with cDC2s
to promote early phases of T cell activation. The discrepancies
stated above, however, suggest a greater level of heterogeneity
than currently appreciated among cDC2s. Future studies to
selectively target different subsets of cDC2s including migratory,
resident and CD301b-expressing cells will help clarify positive
and negative influences on Tfh differentiation.
NON-CONVENTIONAL DCs
Monocyte-Derived DCs
Using the van Gogh model Levin et al. show that while ear
resection does not impair the frequency of monocyte populations
in the draining lymph node, it does result in impaired Tfh
responses to HIV p24 coated nano-particles (31). Similarly,
Kumamoto et al. showed that depletion of monocyte-derived
DCs using anti-Gr1 antibodies also had no impact on Tfh
responses (40). Together, these results suggest that monocyte-
derived DCs are not required for priming Tfh cells.
However, using different models, other groups have come
to the opposite conclusion. Barbet et al. show that Tfh
responses to intraperitoneal E. coli vaccination are TRIF-
dependent, and driven by CD11c+ CX3CR1+ “patrolling”
monocytes. They demonstrate that TRIF-dependent Tfh priming
is unaffected in the absence of cDCs (using Zbtb46-DTR mice)
or inflammatory monocytes (Ccr2−/− mice) (51). Immunization
with a combination of CpG-B and incomplete Freund’s adjuvant
(IFA) results in higher frequencies of Tfh cells as compared
to IFA alone (52). Using Ccr2−/−or Cx3Cr1−/−mice, Chakarov
et al. generated mice with deficiencies in moDCs but not cDCs
to demonstrate that the enhanced Tfh response induced by
CpG-B is driven by IL-6-producing moDCs (52). However,
given that a significant frequency of Tfh cells were induced
in the absence of moDCs (52), one conclusion could be that,
while cDCs play a dominant role in priming Tfh responses,
moDCs enhance this response via IL-6 production. Interestingly,
Germain and colleagues demonstrated that administration of
high doses of DT to Zbtb46-DTR mice triggers infiltration of
CD11b-expressing monocytic populations that are distributed
throughout the lymph node (27). Thus, while these cells may
not form part of the canonical Tfh differentiation pathway, these
results together indicate that under certain conditions, moDCs
can occupy similar functional niches as cDC1s and cDC2s and
can help prime Tfh responses.
Langerhans Cells
The absolute requirement of LCs for humoral responses has
been addressed by several studies using Langerin-diphtheria
toxin receptor mice (31, 40, 53). To delineate which migratory
DC subsets play a role in Tfh responses, Levin et al. used
Langerin-DTRmice to deplete Langerin-expressing DCs i.e., LCs
and cDC1s in the skin (31). Post DT treatment, LCs remain
depleted for more than 2 weeks while cDC1s are replenished
within 1 week. They employed this differential response to
generate mice lacking only LCs (DT administered 2 weeks prior
to immunization) or both LCs and cDC1s (DT administered
2 days prior to immunization). Loss of either LCs alone or
both LCs and cDC1s decreased but did not abrogate Tfh and
antibody responses to HIV p24-coated nano-particles that were
administered in the absence of any other adjuvant. The authors
conclude that while LCs do play a role in Tfh-dependent B
cell responses, migratory cDC2s also contribute to humoral
responses in the skin (31). Corroborating these results, in a
model using OVA and the adjuvant papain, Kumamoto et al.
demonstrate that LCs are not required for humoral responses to
cutaneous antigens (40).
In an earlier study using the same Langerin-DTR mice,
Zimara et al. demonstrated that loss of LCs results in impaired
Tfh induction and early antibody responses (day 10) to
Leishmania major infection (53). However, overall Leishmania-
specific humoral responses (i.e., day 40 post-infection) remain
unaffected. The study further showed that the size of GC is
decreased in mice lacking LCs. These impaired responses are,
however, restricted to Leishmania infection and not seen with
other T-dependent antigens like DNP-KLH (with the adjuvant
aluminum hydroxide). The authors suggest that Leishmania
infection, unlike DNP-KLH and alum, does not lead to
maturation of cDCs and under these circumstances, LCs drive
humoral responses (53).
Yao et al. used transgenic mice expressing human Langerin
(huLangerin), specifically in LCs but not in other DCs (i.e.,
dermal cDC1s, where murine Langerin is expressed) (36).
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Using monoclonal antibodies specific to human Langerin, the
authors demonstrate that targeting antigens to LCs in vivo
efficiently induces antigen-specific Tfh cell responses. The
response generated was dose-dependent and was only generated
against foreign antigens (and not self-antigens like MOG
peptide). Targeting LCs either in the skin and LNs (systemic
administration) or in the skin alone (topical application)
efficiently induced B cell responses including GC B cell formation
and a protective humoral response against lethal influenza
challenge (36). It is interesting to note that as compared to
previously published reports (7, 44), the kinetics of the response
generated by targeting LCs is slightly delayed, i.e., the peak of
the Tfh cell response observed is around day 7 and the peak
of GC B cell expansion is around day 14 (36). One potential
explanation for this is that LCs are known to have significantly
slower migration kinetics with their numbers peaking 3–4 days
post-immunization (even under inflammatory conditions) as
opposed to cDCs that reach the draining cutaneous lymph nodes
18–24 h post-immunization (50, 54, 55).
In the work by Yao et al. LCs were shown to primarily
drive humoral responses when antibodies to Langerin
were administered without an adjuvant (36). Under these
circumstances, the lack of adjuvant would fail to efficiently
induce maturation and migration of migratory cDCs- a pre-
requisite for their ability to induce effective T cell responses.
Indeed, even under inflammatory conditions, expression of
co-stimulatory molecules remain unchanged on LCs that
migrate to the LN, suggesting that under steady state, LCs have a
mature phenotype (54). In contrast, migratory cDCs have higher
expression of co-stimulatory molecules and emigrate in greater
frequencies upon maturation (30, 56) possibly indicating that
these cells play a dominant role under inflammatory conditions
such as in the case of an infection or vaccine response. These
results together suggest that LCs can drive humoral responses
to low-abundance, weakly immunogenic antigens that do not
efficiently induce cDC maturation (36, 53).
DC-DEPENDENT FACTORS REGULATING
EARLY Tfh DIFFERENTIATION
Early differentiation signals required for Tfh cells have been
extensively characterized. Signals that function early in the Tfh
differentiation process, and that are independent of B cells, have
frequently been ascribed to DCs. However, it is important to note
that there is still limited evidence that directly proves that these
are DC-unique factors. This is further complicated by the fact
that multiple DC subsets could play a role in the differentiation
process.
DC Maturation and Pattern Recognition
Receptors
DCs must undergo a maturation process for the induction of a
productive adaptive immune response. Almost 30 years following
Charles Janeway’s proposal, several PAMPs (pathogen-associated
molecular patterns) or DAMPs (danger-associated molecular
patterns) have been identified that are detected by the immune
system via specific groups of germ-line encoded receptors
called Pattern Recognition Receptors (PRRs). These include
Toll-like receptors (TLRs), C-type lectin receptors (CLRs), NOD-
like receptors (NLRs), RIG-I-like receptors (RLRs) and AIM2-
like receptors (ALRs). Engaging these receptors results in DC
maturation and thereby an effector T cell response (57).
TLR agonists have widely been used in induction of Tfh
responses. Notably, TLR3 (39, 58), TLR4 (5, 30, 39, 58) and TLR9
(27, 40, 52) agonists have been shown to effectively drive Tfh
responses in both mice and humans. Kumamoto and colleagues
show that the immunosuppressive effects of CD301b+ cDC2s
is only seen using “Th2-type” adjuvants like papain and that
engagement of TLRs like TLR4 and TLR9 overcomes the Tfh-
inhibiting capacity of this DC subset (40). In a recent study,
Ugolini et al. demonstrate that TLR8 on humanmonocytes senses
microbial viability by binding to bacterial mRNA. The activation
of monocytes by this special class of PAMPs called “vita-PAMPs,”
results in production of IL-12 which in turn drives BCL6
expression and IL-21 production by CD4T cells (59). Barbet et al.
reported that in mice, bacterial viability is detected by CX3CR1+
monocytes via a TRIF-dependent mechanism. The downstream
Type I IFN response along with inflammasome activation drives
Tfh differentiation (51).While the role of IFN signaling in driving
Tfh responses is discussed later, it is important to note that
TLR3 and TLR4 agonists also drive Tfh responses by inducing an
autocrine Type I IFN signal in DCs (58). Using humanmonocyte-
derived DCs, Schmitt et al. compared Tfh inducing capacities of
different TLR agonists and show that TLR4, TLR5, and TLR7/8,
but not TLR2, activation induces IL-21 production from CD4+
T cells, with TLR4 being the most potent followed by TLR5 and
TLR7/8 (5).
Monoclonal antibodies against C-type lectin receptors (CLRs)
have been used to target antigens to specific DC subsets in
vivo and, as described previously, several studies have employed
this approach to study the Tfh-priming capacities of different
DC subsets. Targeting antigen to certain C-type lectin receptors
is alone sufficient to prime Tfh cells and does not require
additional adjuvants. For example, targeting LCs via the CLR
Langerin does not result in LC activation but is sufficient to drive
Tfh cell differentiation in vivo (36). Similarly, Caminschi and
colleagues demonstrate that targeting antigen to cDC1s via the
CLR CLEC9A induces a robust Tfh cell response (37, 38) and
this response is not augmented by co-administering the TLR9
agonist, CpG (38). In contrast, Shin et al. report that effective Tfh
cell differentiation is observed when antigen is targeted to cDC2s
via the CLR DCIR2 in the presence of TLR3 (Poly I:C) or TLR4
(LPS) agonists (39).
There are a limited number of studies addressing the role
of other groups of PRRs in driving Tfh differentiation. While
the role of NLRs in priming Tfh cells has not been directly
addressed, alum, a potent activator of the NLRP3 inflammasome
(60, 61), has been used as an adjuvant in several studies (6, 62, 63).
Further, IL-1β, an effector cytokine produced downstream of
inflammasome activation (57), also plays a role in priming Tfh
cells, as will be discussed later. Regarding the role of RLRs,
one study demonstrated that co-administering influenza antigens
with 5′ ppp-double-stranded RNA, a RIG-I ligand, enhances Tfh
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differentiation and antibody responses to influenza via a Type I
IFN-dependent mechanism (64).
Antigen Presentation
The strength and duration of antigen presentation plays a critical
role in determining the outcome of CD4+ T cell responses, i.e.,
T effector cells versus Tfh differentiation (65). Using a pigeon
cytochrome C (PCC) model, Fazilleau et al. demonstrated that T
cells with higher antigen affinity preferentially differentiate into
Tfh cells (66). Tfh cells have stronger affinity for peptide-MHC
II complexes and a more restricted TCR repertoire as compared
to T effector cells (66). In addition to TCR affinity, increased
TCR signals (using high antigen concentrations) are required for
maximal IL-21 production (66). Moreover, increasing the antigen
dose (11) or gradually increasing antigen administration over 2
weeks (67) boosts the generation of both Tfh and GC B cells.
Thus, antigen dose is tightly linked to both Tfh induction and
the magnitude of GC responses. In contrast, both high and low
affinity antigen-specific T cell clones equally differentiate into
Tfh cells in mice immunized with Friend’s virus (68). This study
used a chronic retroviral infection model and the authors suggest
that the differences in their study as compared to Fazilleau et al.
is probably due to antigen availability. Thus, they hypothesize
that under conditions of limiting antigen availability, high TCR
avidity would drive Tfh cell differentiation (68). However, TCR
avidity, as in the case of the previous study, does impact IL-21
production, suggesting that some features of Tfh differentiation
are indeed TCR-intrinsic (68).
Nevertheless, the contrasting results of these studies suggest
that simple affinity of TCR to peptide-MHC II complexes,
i.e., the receptor occupancy model, would not explain Tfh
versus T effector cell differentiation. An alternative kinetic
proofreading model suggests that the duration of interaction
between TCR and peptide MHC II complexes (i.e., DC-T cell
interaction times) is a better predictor of the outcome of the
T cell response. Using single cell clones, Tubo and colleagues
elegantly provide support for this model. They show that
longer dwell time between TCR and peptide-MHCII, rather
than TCR affinity, preferentially drives Tfh cell differentiation
(69). In a recent study, Benson et al. visualized this process
in vivo to show that the time of antigen presentation by DC
to CD4+ T cells is critical for Tfh differentiation in vivo (7).
Immunizing mice sub-cutaneously with 200 nm sized antigen-
coated nanoparticles efficiently primed Tfh responses and
protective antibody responses to influenza. Using multiphoton
imaging, DC and antigen-specific CD4+ T cell interactions were
imaged in vivo. The authors defined 3 stages of DC-T cell
interaction over the course of the immune responses: Stage 1 (0–
8 h), Stage 2 (12–24 h), and Stage 3 (48–72 h) post-immunization.
Interactions longer than 10min between DC-CD4+ T cells at
Stage 3 were required for efficient Tfh cell priming. Disrupting
MHCII-TCR binding at this stage impaired Tfh cell frequencies,
suggesting that sustained antigen presentation is required for
Tfh cell differentiation (7). These results together indicate that
DC subsets that stably express antigen-MHCII complexes are
probably superior at priming Tfh cells. Since cDC2s are more
efficient than cDC1s in processing antigen for MHCII, this could
explain why this subset seems to bemore effective in Tfh priming,
as discussed above (20, 70). However, experimental models in
which antigen is specifically targeted to cDC1s could compensate
for this difference and thereby enhance the ability of cDC1s to
promote Tfh differentiation (37, 38).
Co-stimulatory Molecules
Tfh priming requires a variety of co-stimulatory molecules
including B7 family members, CD40L, OX40L, and ICOSL
(63). The most extensively studied co-stimulatory molecule
with regards to Tfh priming is OX40L. However, studies have
revealed, at least in part, that CD28 engagement and/or CD40L
engagement leads to upregulation of OX40 on T cells (63).
Early reports demonstrated that CD28-deficient mice have
impaired GC and humoral responses (71). Mice overexpressing
CTLA4 (mCTLA4-Hγ1 transgene), the inhibitory ligand for
CD28, also showed similar impairment in T-dependent B cell
responses (72). However, Lane and colleagues in later studies
demonstrated that the loss of these humoral responses was
primarily due to impaired OX40 expression. OX40 is upregulated
on naïve T cells following CD28 activation and activation of
T cells by OX40L promotes expression of IL-4 and CXCR5
(73, 74). Interestingly, constitutive expression of OX40L by DCs
(using CD11c-OX40L transgenic mice) leads to increased Tfh
cell differentiation; however, this is also dependent on CD28
signaling (74). A recent study by Watanabe et al. using Cre-
mediated deletion of CD80 and CD86 in DCs illustrated that
CD28 signaling at the stage of T-DC interaction is critical for
initial priming and expansion of T cells (75). In contrast, loss
of CD80 and CD86 in the B cell compartment did not affect
the generation of Tfh cell or GC B cells nor humoral responses
in terms of affinity maturation and serum IgG levels (75).
Collectively, these studies demonstrate a critical role of DCs in
delivering CD80/CD86 co-stimulatory molecules during pre-Tfh
differentiation for optimal Tfh and GC responses.
Patients with CD40L deficiency as well as CD40-deficient
mice show impaired Tfh cell frequencies (76, 77). Given that
CD40 activation leads to OX40L expression on both murine
and human DCs (78, 79), the Tfh defects seen in the absence
of CD40 could indeed be a downstream effect of abrogated
OX40/OX40L signals. In line with this, Fillatreau et al. report that
Cd40−/− mice, like Ox40−/−mice, have impaired accumulation
of T cells in follicles. CD40 is required for CXCR5 expression
in T cells (80). Restoring CD40 expression in DCs but not B
cells, either using mixed bone marrow chimeras or by adoptive
transfer of CD40+ DCs, restores this response in Cd40−/− mice.
Furthermore, treatingCd40−/− mice with OX40L-huIgG1 fusion
proteins readily rescues CD4+ T cell migration into follicles
(80). However, administration of agonistic OX40 antibodies
during LCMV infection diverts Tfh differentiation to T effector
differentiation by inducing Blimp-1 expression (81), suggesting
that the role of OX40 signaling in Tfh differentiation is context-
dependent.
These results suggest that Tfh priming is primarily regulated
by OX40 signaling downstream of CD28 and CD40L. However,
Akiba et al. compared the effects of all three co-stimulatory
molecules on Tfh priming in vivo and clearly demonstrate
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that while CD28 and CD40 are indeed required for Tfh
cell differentiation and GC B cell responses, the requirement
for OX40 signaling is strain- and immunization site-specific
(76). The authors immunized various mouse strains, including
BALB/c and C57BL/6, at different sites and compared OX40
expression on Tfh cells in the spleens and in skin-draining LNs.
They show that OX40 blocking antibodies only impair GC and
Tfh responses in LNs of C57BL/6 mice but not in BALB/c mice,
possibly since OX40L expression is observed only in LN but
not splenic Tfh cells in C57BL/6 mice post-immunization (76).
The requirement for CD28, beyond OX40 upregulation, in early
Tfh cell responses is further demonstrated in a study by Smith
and colleagues (82). Cd28flox/flox Ox40Cre/+ mice were used to
block CD28 signaling after T cell priming and expansion. The
authors show that these mice have reduced frequencies of Tfh
and GC B cells in response to intranasally administered influenza
A, as compared to control mice. Loss of CD28 in activated
T cells, results in increased apoptosis and impaired BCL6 and
ICOS expression in Tfh cells (82). These results suggest that
persistent CD28 stimulation, beyond early naïve T cell activation,
is required for Tfh cell differentiation and maintenance as well as
functional humoral responses (82).
A recent study by Tahiliani et al. demonstrates that in amurine
model of vaccinia virus infection, OX40-deficient mice have
impaired Tfh and B cell responses (83). Blocking OX40L during
and after Tfh cell generation leads to a significant reduction in
Tfh, GC Tfh and GC B cell frequencies (83). Finally, OX40L-
expressing DCs were seen in bridging channels in the spleen
and also co-localized with OX40+ T cells, suggesting that cDC2s
could in part provide some of these signals during Tfh cell
priming (83). Further, TSLP-activated human DCs prime IL-
21- and CXCL13-producing CXCR5+ PD-1+ Tfh cells in vitro.
Blocking OX40L, but not ICOSL, in this system reduces IL-21
and CXCL13 production. It is important to note that while BCL6
expression is reduced in CXCR5hi PD1hi cells, blocking OX40L
in this system does not reduce Tfh cell frequencies (15). Together,
these results indicate that the requirement for OX40L during Tfh
cell differentiation is not absolute, but under specific conditions,
could regulate certain facets of Tfh cell differentiation.
ICOS signaling plays a central role in Tfh cell priming. ICOS-
deficient mice and humans have impaired Tfh cell and GC
B cell frequencies, reduced T cell localization to follicles and
impaired humoral responses (76, 77). Roquin 1 and Roquin 2
are RNA-binding proteins that play an important role in post-
transcriptional repression of ICOS expression. Combined loss
of Roquin 1 and Roquin 2 (84, 85), or loss of mir-146a (also a
negative regulator of ICOS) (86) specifically in T cells, increases
ICOS expression, resulting in spontaneous accumulation of
Tfh and GC B cells in mice (84–86). B cell-specific ablation
of ICOSL results in a similar loss of Tfh cell differentiation
as ICOSL knockout mice, which suggests that ICOS signaling
primarily plays a role during the B cell phase of Tfh priming
(87). Similarly, blocking ICOSL in vitro did not impair human
Tfh cell differentiation by TSLP-activated DCs (15). In contrast,
Choi et al. demonstrate that early ICOS signaling is required
for BCL6 expression and Tfh cell commitment as Icos−/− T
cells failed to differentiate into Tfh cells as early as day 3
post-immunization (88). The authors also show that loss of
B cells had no impact on Tfh cell frequencies 3 days post-
immunization, suggesting that this stage was B cell-independent.
Further, adoptive transfer of antigen-loaded DCs was sufficient
to induce BCL6 and CXCR5 expression in T cells confirming
that this early stage of Tfh cell differentiation is indeed DC-
dependent. The impaired differentiation of Icos−/− T cells to Tfh
cells early in the response suggests that ICOSL signaling by DCs
is critical for Tfh cell priming. Further, ICOS signaling during
this first stage is required for BCL6 expression by Tfh cells, which
the authors show in turn is critical for CXCR5 expression (88).
Together, these findings highlight that ICOS is important for
multiple stages of Tfh differentiation and is provided by both DCs
and B cells.
Finally, NOTCH signaling also regulates Tfh cell
differentiation. Loss of NOTCH 1 and 2 specifically in CD4+
T cells leads to reduced Tfh cell frequencies, impaired IL-4
production by Tfh cells and concomitantly, reduced GC B cell
and IgE responses (89, 90). While NOTCH signaling controls
IL-4 production by Tfh cells (90), NOTCH-deficient Tfh cells
also fail to downregulate BLIMP1 (PRDM1) or upregulate BCL6,
Cmaf, and IL-21, in an IL-4-independent manner (89). DC-
specific deletion of the NOTCH ligand, the E3 ubiquitin ligase
Mind bomb1 (MIB1) also impairs early Tfh cell differentiation.
Tfh cell frequencies in these mice are eventually comparable
to controls at later stages of the response indicating that
requirement for DC-derived NOTCH signals is not absolute.
The authors also demonstrate that depletion of NOTCH ligands
on B cells and follicular DCs has no impact on Tfh cell priming
(90).
Cytokines
The cytokine milieu in SLOs plays a critical role in polarizing T
cells either toward Tfh or other T effector fates. Depending on
the PAMPs or DAMPs associated with the antigen encountered,
DCs secrete cytokines that could significantly influence the
outcome of the T cell response. Given that different DC subsets
preferentially express distinct cytokines, this may specialize them
for driving the polarization of different T cell subsets. Further,
as discussed previously, distinct DC subsets occupy unique
niches within the SLOs; therefore, a combination of DC-intrinsic
differences in cytokine production in combination with cells in
the niche could favor Tfh differentiation versus other T effector
fates.
IL-6
In the mouse, IL-6 is one of the first cytokine signals to
influence the early stages of Tfh differentiation. IL-6 signals
via STAT3 and this pathway induces early expression of BCL6
in T cells (91, 92). Deficiency of IL-6 or STAT3 impairs Tfh
differentiation and antibody responses in vivo (91, 93). DCs
produce copious amounts of IL-6 in response to stimulation
with various PAMPs or CD40 activation (2). Adoptive transfer
of antigen-pulsed IL-6-sufficient DCs but not IL-6-deficient DCs
leads to efficient antibody responses in vivo (93). DC-specific
deletion of Blimp1 in mice results in a spontaneous lupus-like
phenotype characterized by increased Tfh cell frequencies and
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autoantibody production (94). The authors demonstrate that
BLIMP1 deficiency causes increased IL-6 production by DCs.
Further, Il-6 heterozygous DC-specific Blimp1-deficient mice
(Il-6+/− DCBlimp1ko), in which IL-6 expression is no longer
elevated, have reduced GC and Tfh cell responses compared
to DCBlimp1ko, suggesting that DC-derived IL-6 drives the
responses observed in these mice (94). In a subsequent study,
Kim et al. defined IL-6-dependent and -independent pathways
by which BLIMP1 also regulates the expression of Cathepsin S,
an endolysosomal protease which influences antigen processing,
suggesting this as an additional mechanism for the observed
lupus-like phenotype (95). They showed that DCs from BLIMP1-
deficient mice induced IL-21 expression in co-cultured T cells
and that this is abrogated in the presence of a Cathepsin S
inhibitor (95).
These results indicate that DCs could indeed be the source of
IL-6 for Tfh cell differentiation. However, other studies suggest
that, rather than driving early Tfh cell differentiation, DC-derived
IL-6 instead fine-tunes the phenotype of newly primed Tfh
cells, with other cell types producing the IL-6 that is required
for early Tfh differentiation. Using adoptively transferred IL-
6-deficient antigen-pulsed DCs, Andris and colleagues show
that DC-derived IL-6 has no impact on Tfh cell frequencies or
CXCR5, PD1 and BCL6 expression (96). This is in line with
a report from Chen et al. who, using mixed bone marrow
chimeras, report that IL-6 deficiency in radio-resistant (such as
stromal cells) but not radio-sensitive hematopoietic cells (such
as DCs), impacts CXCR5 and BCL6 expression in Tfh cells (62).
However, Andris and colleagues also show that IL-6-mediated
STAT3 signaling suppresses GATA3 expression in Tfhs. Loss of
DC-derived IL-6 results in decreased IL-21 and increased IL-4
production by Tfh cells, resulting in increased IgE responses (96).
These results indicate that IL-6 production from stromal cells
as well as DCs have non-redundant functions during Tfh cell
differentiation.
IL-12
IL-12 has been shown to play a critical role in Tfh cell
differentiation in human T cells (5). Triggering of certain pattern
recognition receptors like TLRs induces IL-12 production by
DCs (2). In two separate studies, IL-12, and to a lesser extent
IL-23, were able to induce IL-21 from human CD4+ T cells
activated in vitro (5, 97). IL-21-expressing T cells express CXCR5
and ICOS and promoted B cell help in vitro (5, 97). Similarly,
allogenic stimulation of T cells with DCs exposed to different
heat-killed bacteria, resulted in IL-21 expression by T cells which
in turn regulated antibody production by B cells in vitro. This
process is IL-12-dependent, as inhibiting IL-12 in vitro abrogated
these responses (5). Human cDC2s produce higher levels of IL-
12 and IL-6 as compared to cDC1s in response to a variety of
TLR ligands (98, 99). This might explain, in part, why TSLP-
activated human cDC2s are superior to cDC1s in activating and
inducing IL-21 production from T cells (15). Using adoptive
transfer of DCs, Andris and colleagues demonstrated that loss
of IL-12 does not impact murine Tfh cell differentiation (96). In
contrast to human cDC2s, murine cDC2s actually produce less
IL-12 (30, 100). Therefore, the role of IL-12 appears to be different
in human vs. murine Tfh-DC interactions and further work
remains to be done on what accounts for these species-specific
effects.
Type I IFN
Type I IFN and IL-27 modulate Tfh cell differentiation.
Interferon-alpha/beta receptor-deficient (Ifnar−/−) mice have
impaired Tfh cell and antibody responses as compared to control
mice when immunized with NP-OVA and LPS (58). IFNAR
deficiency in either DCs or radio-resistant cells also results in
reduced frequencies of Tfh cells. Further, Ifnar-deficiency in DCs
results in reduced IL-6 production (58). As discussed previously,
IL-6 production from stromal cells and DCs seems to non-
redundantly impact Tfh cell differentiation and these data further
support this hypothesis.
While IFN-induced IL-6 production provides one potential
mechanism, other pathways downstream of IFNAR signaling
have also been shown to drive Tfh cell responses. Gringhuis
et al. demonstrate that autocrine IFNAR signals in human
DCs can promote IL-27 production that in turn drives Tfh
cell differentiation (101). They show that treating human DCs
with fucose, an agonist of the C-type lectin receptor DC-
SIGN, activates IKKε, a member of the non-canonical IKK
kinase family. This pathway synergizes with an autocrine Type
I IFN signal to drive IL-27 production. The IL-27 produced
by the DCs enhances BCL6 and IL-21 expression in T cells
(101). In line with this, using Il27rα−/− mice, Batten et al.
demonstrated that IL-27 promoted IL-21 production and Tfh
cell survival (102). A recent study by Blander and colleagues
also demonstrated an alternative pathway by which Type I
IFN regulated Tfh differentiation (51). They demonstrated that
autocrine IFNAR signals promoted Caspase 1- and Caspase
11-mediated production of IL-1β by DCs. In T cells, IL-1β
signals via IL1R1 and drives expression of BCL6, CXCR5,
and ICOS. In addition, IFNAR signaling in Tfhs directly
induces production of IL-21 (51). However, this study also
shows that CX3CR1+ CCR2− monocyte-derived DCs and
not cDCs drive these Tfh responses (51). The presence of
multiple pathways by which IFNAR signaling regulates Tfh
cell differentiation raises the possibility that depending on
the antigen encountered, different DC subsets could utilize
alternative IFNAR-dependent pathways to prime T-dependent B
cell responses.
IL-2
IL-2 is a negative regulator of Tfh cell differentiation. IL-2
induces BLIMP-1 expression in T cells which suppresses BCL6
and downregulates CXCR5 (1). Further, IL-2-mediated mTORC1
activation of AKT also suppresses Tfh cell differentiation (103).
Under certain stimuli, DCs have been shown to produce IL-2,
a process that is counter-productive for Tfh cell priming (2).
However, a recent study by Cyster and colleagues demonstrates
that certain DC subsets like cDC2s express the IL-2 receptor
alpha chain, CD25 (35). However, cDC2s do not respond to IL-
2, as seen by STAT5 phosphorylation. The authors suggest that
both soluble and secreted CD25 expression by cDC2s creates
a “cytokine-sink” for IL-2. Limiting concentrations of IL-2 in
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the T-B border makes this niche then favorable for Tfh cell
differentiation (35). However, in our studies, while we did find
higher expression of CD25 on lung cDC2s, we could not find
evidence supporting the role of DC-dependent CD25 expression
on Tfh responses (30). Given that other cells in the T-B border
including activated B cells express CD25 (104), we hypothesize
that multiple cell types could cooperate to create an effective IL-2
sink.
THE THREE-STEP DIFFERENTIATION
MODEL
Spatio-temporal distribution of lymphocyte subsets within the
SLOs are critical for efficient Tfh cell priming. Based on the
literature reviewed here, the following conclusions can be drawn
regarding DC subsets and Tfh priming.
1. DC subsets occupy distinct regions within lymphoid organs.
Migratory cDC1s, resident cDC1s and LCs are found within
the T cell zones, migratory cDC2s are located in the T-B
border region (including the IFZ) and resident cDC2s reside
in the lymphatic sinuses (30, 45).
2. Excluding antigens from certain DC subsets or depletion of
specific DC subsets does not impair naïve T cell activation
(27, 30, 31), suggesting that a redundancy exists in this step
of T cell priming.
3. Antigen availability in SLOs determines which antigen
presenting cells (APCs) are able to support Tfh priming.
Decreasing antigen concentration progressively increases the
dependency on APCs that are more effective in priming Tfh
cells (Figure 3).
4. Distinct DC subsets can sequentially prime T cell responses
(26).
5. Early after activation, naïve CD4+ T cells differentiate into
BCL6+ pre-Tfh cells (9) and migrate to the T-B border - a
process regulated by multiple factors including CCR7 (105),
CXCR5 (44, 62, 105), and EBI2 (35). Pre-Tfh cells differentiate
in the T-B region to Tfh cells (44). This process is initially B
cell-independent and DC-dependent (6, 44, 63, 88).
6. Tfh cells interact with antigen-bearing activated B cells and
mature into effector Tfh cells (1).
Based on these data, we propose a three-step model for Tfh
cell differentiation under conditions that deliver sufficient free
draining antigen to LNs (e.g., high antigen doses, footpad
or intra-auricular immunization, or infection within the LN)
(Figure 4).
1. Antigen transport and naïve T cell activation: DCs can
access antigens in three ways (Figure 2):
• Migratory cDCs (and LCs) phagocytose antigen in situ and
then migrate to the LNs
• LN-resident cDC2s lining the lymphatic sinus endothelium
phagocytose free draining antigen from the lymphatics
• Antigen transported by migratory DCs can be transferred
to resident DC subsets in the LNs
FIGURE 3 | Antigen availability and APC dependency. We propose that
antigen availability in secondary lymphoid organs (SLOs) determines which
antigen presenting cells (APCs) are able to support Tfh priming. At very high
antigen concentrations B cells can serve as the sole APC to support Tfh
development. Decreasing antigen concentrations progressively increases the
dependency on APCs that are more effective in priming Tfh cells. Migratory
cDC2s are the most potent Tfh-priming APC and are both necessary and
sufficient at low antigen concentrations.
• Any of these DC subsets upon antigen acquisition can
activate naïve T cells. These T cells migrate to the T-B
border in a CXCR5- and/or EBI2-dependent process.
2. Pre-Tfh differentiation by migratory cDC2s: Migratory
cDC2s home to the T-B border and this process is regulated
by a number of factors including CCR7 (106), CXCR5 (2,
30, 43) and EBI2 (48). As migratory cDC2s uniquely position
themselves in the IFZ, they will efficiently support pre-Tfh
differentiation. This makes cDC2s increasingly important
when the level of antigen in the SLO is limiting. In the absence
of free draining antigen, migratory DCs can accomplish both
step one and step two.
3. Tfh commitment by B cells: As has been extensively
described, B cells become the major antigen presenting cell
in the final stage and provide signals including ICOSL/ICOS,
CD40/CD40L, and CD84/CD84-SAP to complete Tfh cell
differentiation (1, 2, 63).
SUMMARY AND FUTURE DIRECTIONS
DCs are heterogeneous, and multiple subsets have been
implicated in priming Tfh cells. Although our three-step model
incorporates these findings, it is important to bear in mind
that there is currently no definitive evidence clarifying the
individual role of each of these DC subsets in Tfh cell
differentiation. It is likely that the type and body location
of immune insult determines the DC subsets responsible.
The biggest hurdle toward addressing this is the ability to
specifically deplete either resident or migratory cDC subsets in
vivo. Identifying factors that uniquely drive the development,
maturation, or migration of either resident or migratory cDC1s
and cDC2s would be critical for the generation of such murine
models.
While many Tfh cell differentiation factors including
cytokines and co-stimulatory molecules have been described,
it still remains unclear whether DCs are indeed the primary
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FIGURE 4 | Three-step model of Tfh differentiation. (a) Step 1—Naïve T cell activation phase: Upon antigen acquisition any of the DC subsets or Langerhans cells can
activate naïve T cells. These T cells downregulate CCR7 and upregulate CXCR5 allowing migration to the T-B border in an EBI2-dependent manner. It is unclear which
co-stimulatory molecules and cytokines are required during this phase. (b) Step 2—Pre-Tfh phase: Migratory cDC2s home to the T-B border and this process is
regulated by a number of factors including CCR7, CXCR5 and EBI2. Migratory DCs can accomplish both step one and step two. (c) Step 3—Tfh commitment phase:
B cells are the major antigen presenting cell in this final step and provide signals to complete Tfh cell differentiation. (d) Tfh effector phase: Mature Tfh cells enter the
germinal center where they promote survival, affinity maturation and class switch recombination of B cells.
source of these factors. If so, which DC subsets provide
them, at what stage during Tfh differentiation are these
produced, where within the SLO are they secreted, and is this
in conjunction with antigen presentation? Depletion of these
factors within specific DC subsets would be one approach
toward addressing these questions. Further, given that stromal
cells and DCs appear to secrete some of the same factors that
drive Tfh cell differentiation (58, 62), it would be critical to
delineate if these cell types, which may occupy the same niches
within the SLOs, act in concert to efficiently induce humoral
responses.
While the migration of T cells from the T cell zone to the
T-B border, and then to the follicle during Tfh differentiation,
is well studied, there remains much to be understood about the
spatio-temporal dynamics of this process with respect to T cell
interactions with specific DC subsets. In other words, during
the DC-phase of Tfh cell differentiation, do the differentiating
T cells sequentially encounter different DC subsets? What
specific signaling pathways and transcriptional programs are
activated at each step of this process that then drives the
next step of Tfh cell differentiation? Development of advanced
microscopic techniques likemulti-photonmicroscopy andmulti-
parameter immunofluorescence to simultaneously visualize T
cells and antigen-bearing DC subsets would be required to
address these questions. These techniques could be used in
conjunction with next generation sequencing platforms such as
single-cell RNA-Seq and spatial transcriptomics to identify the
impact of different DC subsets on specific stages of Tfh cell
differentiation.
Finally, Tfh cells can play either a beneficial or detrimental
role in different diseases. First, Tfh cells are crucial in mediating
protective antibody responses against pathogens as well as
driving effective vaccine responses. However, we suggest that
current vaccination strategies may be suboptimal in reaching
DCs that are most efficient in priming Tfh responses (30). On
the other hand, Tfh cells have been implicated in a diverse range
of diseases such as allergy, autoimmunity, transplant rejection,
and even cancer (107–112). Currently, little is known regarding
the DC-Tfh axis in the context of disease. Work will be needed
to determine how DCs impact disease initiation, progression,
or severity by controlling the magnitude and/or type of Tfh
response. Manipulation of DCs could potentially provide a
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therapeutic avenue to correct “misguided” or inadequate Tfh
responses.
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